The pharmaceutical industry has a continuing requirement for new therapeutics, in turn relying on a steady pipeline of new drug leads.

Proteomics International has taken a different approach to satisfying this need.

Working with peptides derived from the venoms of scorpions, centipedes and spiders, it has developed an entirely new way of validating its leads.

The key technology is mass spectrometry and a proprietary process called Bioven. Proteomics International takes the venoms from central Australia’s desert arthropods and other regions, and following pre-processing analyses the venoms through its mass spectrometers. The final phase uses computer based screening to determine peptide identity and predict, by homology matching, the function of the found peptides.

The remarkable finding is that by using this uniquely sensitive process, up to five times more peptides can be found in one venom than previously thought.


Targeted, proprietary and proven mass spectrometry platform – Bioven

The success rate of a pilot study to identify lead compounds revealed that the Bioven platform was 100 times greater than industry standard hit-rate for small molecule primary screens.



Why venoms?

There is a history of successful commercial outcomes in the field of venoms. Every venomous creature has developed over millions of years a selected set of peptides and proteins that have specific functions whether in defence or attack. This process is highly conservative – Nature wastes nothing.

Bioven is finding new molecules which may become anti-microbials, analgesics, anti-hypertensives and more. The process is an automated, predictive, high-throughput system with the capacity to process a large number of venoms to identify peptides with therapeutic potential in a short period of time.

In the fast changing world of therapeutic technologies there is growing expertise in taking peptides forward to pre-clinical testing. Critically important, venom peptides are already proven as soluble and stable. And, with in-house synthesis capacity, Proteomics International can produce peptides in quantities sufficient for early validation, and gain knowledge on the practicality of large scale manufacture.

For further information please direct enquiries to

  • This field is for validation purposes and should be left unchanged.